Literature DB >> 16815396

Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study.

Anne J Lee1, Jie Jin Wang, Annette Kifley, Paul Mitchell.   

Abstract

PURPOSE: To evaluate the association between open-angle glaucoma (termed glaucoma) and 9-year mortality in an older population-based cohort.
DESIGN: Population-based cohort. PARTICIPANTS: Three thousand six hundred fifty-four persons aged 49 to 97 years (82.4% of the eligible population), residents of the Blue Mountains, west of Sydney, Australia.
METHODS: At baseline (1992-1994), glaucoma was diagnosed from congruous typical glaucomatous visual field changes (full-threshold fields) and optic disc cupping (stereo-optic disc photography). Demographic information from baseline participants was matched with the Australian National Death Index data (December 2001) to obtain the number and causes of deaths. Cox proportional hazards regression analysis, controlling for age, male gender, diabetes, hypertension, heart disease, stroke, use of oral beta-blockers, current smoking history, alcohol use, myopia, and nuclear cataract were performed to assess hazard ratios for cardiovascular mortality. Adjustments for all-cause mortality also included history of cancer. MAIN OUTCOME MEASURES: Cardiovascular and all-cause mortality.
RESULTS: At baseline, glaucoma was diagnosed in 108 participants (3.0%). Of 873 deaths (23.9%) before January, 2002, 312 people (8.5%) died of cardiovascular events. The age-standardized all-cause mortality was 24.3% in persons with and 23.8% in those without glaucoma, whereas cardiovascular mortality was 14.6% in persons with and 8.4% in those without glaucoma. After multivariate adjustment, those with glaucoma had a nonsignificant increased risk of cardiovascular death (relative risk [RR], 1.46; 95% confidence interval [CI], 0.95-2.23). Increased cardiovascular mortality was observed mainly in glaucoma patients aged <75 years (RR, 2.78; 95% CI, 1.20-6.47). Further stratified analyses showed that cardiovascular mortality was higher among those with previously diagnosed glaucoma (RR, 1.85; 95% CI, 1.12-3.04), particularly in those also treated with topical timolol (RR, 2.14; 95% CI, 1.18-3.89).
CONCLUSIONS: Findings from the Blue Mountains Eye Study demonstrate an increased cardiovascular mortality in persons with previously diagnosed glaucoma. There was a suggestion of higher cardiovascular mortality in glaucoma patients using topical timolol that merits further study.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815396     DOI: 10.1016/j.ophtha.2006.02.062

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

Review 1.  Depression in patients with heart disease: the case for more trials.

Authors:  Stanley S Liu; Roy C Ziegelstein
Journal:  Future Cardiol       Date:  2010-07

2.  Non-standard vision measures predict mortality in elders: the Smith-Kettlewell Institute (SKI) study.

Authors:  Lori A Lott; Marilyn E Schneck; Gunilla Haegerström-Portnoy; John A Brabyn
Journal:  Ophthalmic Epidemiol       Date:  2010-08       Impact factor: 1.648

3.  Seeing is believing: NO therapy for glaucoma? Focus on "Role of nitric oxide in murine conventional outflow physiology".

Authors:  Natasha M Rogers; Jeffrey S Isenberg
Journal:  Am J Physiol Cell Physiol       Date:  2015-06-24       Impact factor: 4.249

Review 4.  Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

Authors:  David C Broadway; Heidi Cate
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

5.  Ten-year outcomes in newly diagnosed glaucoma patients: mortality and visual function.

Authors:  Tarun Sharma; John F Salmon
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

6.  Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data.

Authors:  Aimee Teo Broman; Harry A Quigley; Sheila K West; Joanne Katz; Beatriz Munoz; Karen Bandeen-Roche; James M Tielsch; David S Friedman; Jonathan Crowston; Hugh R Taylor; Rohit Varma; M Cristina Leske; Boel Bengtsson; Anders Heijl; Mingguang He; Paul J Foster
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

Review 7.  [Self-relaxation techniques for glaucoma patients. Significance of autogenic training, hypnosis and music therapy].

Authors:  T Bertelmann; I Strempel
Journal:  Ophthalmologe       Date:  2016-02       Impact factor: 1.059

8.  Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucoma.

Authors:  Jordana K Schmier; David W Covert; Edmund C Lau
Journal:  Clin Drug Investig       Date:  2012-12       Impact factor: 2.859

9.  Ophthalmic drugs as part of polypharmacy in nursing home residents with glaucoma.

Authors:  Matthias Huber; Marita Kölzsch; Ralf Stahlmann; Werner Hofmann; Juliane Bolbrinker; Dagmar Dräger; Reinhold Kreutz
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

10.  The landscape of genetic susceptibility correlations among diseases and traits.

Authors:  Jung Hun Ohn
Journal:  J Am Med Inform Assoc       Date:  2017-09-01       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.